Abuse of guaifenesin-containing medications generates and excess of a carboxylate salt of beta-(2-methoxyphenoxy)-lactic acid, a guaifenesin metabolite, and results in urolithiasis

Urology

Volumn 54, Issue 1, 1999, Pages 23-27

  Pickens, Cynthia L ^a   Milliron, Abby R ^a   Fussner, Alice L ^a   Dversdall, Bart C ^a   Langenstroer, Peter ^b   Ferguson, Scott ^c   Fu, Xiong ^d   Schmitz, Francis J ^d   Poole, Edward C ^a  

^a UroCor Incorporated   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACID DERIVATIVE; GUAIFENESIN;

ADULT; ARTICLE; CHEMICAL STRUCTURE; CLINICAL ARTICLE; DRUG ABUSE; DRUG ANALYSIS; ELECTRON MICROSCOPY; FEMALE; HUMAN; INFRARED SPECTROSCOPY; MALE; MASS SPECTROMETRY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; UROLITHIASIS;

ADOLESCENT; ADULT; CARBOXYLIC ACIDS; FEMALE; GUAIFENESIN; HUMANS; MALE; MIDDLE AGED; SALTS; URINARY CALCULI;

EID: 0033169109     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00031-X     Document Type: Article

References (14)

1. Rodman J, Seidman C, and Jones R: No More Kidney Stones. New York, John Wiley & Sons, 1996, pp 5 and 20.
2. Bruce G.R., Munch L.C., Hoven A.D., et al. Urolithiasis associated with the protease inhibitor indinavir. Urology. 50:1997;513-518.
3. Natsch S., Hekster Y.A., Keyser A., et al. Newer anticonvulsant drugs role of pharmacology, drug interactions and adverse reactions in drug choice . Drug Saf. 17:1997;228-240.
4. Jones G., Hogan D.B., Yent D.B., et al. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis. Can Med Assoc J. 155:1996;955-961.
5. 1H FT NMR Spectra. vol 2:1993;180 Aldrich Chemical, Milwaukee.
6. Marle E.R. The aryl ethers of glycide, glycerol, and glycerol-a-monochlorohydrin. J Chem Soc. 101:1912;305-317.
7. Yale H.L., Pribly E.J., Braker W., et al. Muscle-relaxing compounds similar to 3-(o-toloxy)-1,2-propanediol. I. Aromatic ethers of polyhydroxy alcohols and related compounds. J Am Chem Soc. 72:1950;3710-3716.
8. Federal Register 21 CFR Part 341. Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for OTC Human Use; Expectorant Drug Products for Over-the-Counter Human Use; Final Monograph; Final Rule. Volume 54, 1989, pp 8454-8509.
9. Vandenheuvel W.J.A., Smith J.L., Silber R.H. β-(2-Methoxyphenoxy)lactic acid, the major urinary metabolite of glyceryl guaiacolate in man. J Pharm Sci. 59:1970;1997-1998.
10. Maurer H.H. Identification and differentiation of barbiturates, other sedative-hypnotics and their metabolites in urine integrated in a general screening procedure using computerized gas chromatography-mass spectrometry. J Chromatogr. 530:1990;307-326.
11. Federal Register 21 CFR Parts 1310 and 1313. Elimination of Threshold for Ephedrine. Volume 59, 1994, p 51365.
12. Two-Way package ingredient information. Manufactured for Compare Generiks, Hauppauge, New York, by BDI Pharmaceuticals, Indianapolis, Indiana.
13. Efedrin package ingredient information. Manufactured for the Hammer Corporation, Atlanta, Georgia, by an undisclosed manufacturer.
14. Oklahoma Vehicle, Criminal, Alcohol, Tobacco & Drug, and Boating Laws. 1996 Edition. Uniform Controlled Dangerous Substances Act; Amendatory 63 O.S. 1991, section 2-210.